1.A case of agranulocytosis following psychotropic agent therapy.
Journal of Korean Neuropsychiatric Association 1993;32(4):589-593
No abstract available.
Agranulocytosis*
2.The effect of granulocyte colony stimulating facto(G-CSF) in a patient with propylthiouracil-induced agranulocytosis.
Kwang Hyen YOU ; Seung Si SON ; Seung Yel SONG ; Myoung Seon PARK ; Yong Gu LEE ; Chung Gu CHO
Journal of Korean Society of Endocrinology 1993;8(3):347-350
No abstract available.
Agranulocytosis*
;
Granulocytes*
;
Humans
3.Rapid preoperative preparation for thyroidectomy of a severely hyperthyroid patient with Graves’ Disease who developed agranulocytosis
Daveric Pagsisihan ; Aimee Andag-Silva ; Olivia Piores-Roderos ; Ma. Ailsa Escobin
Journal of the ASEAN Federation of Endocrine Societies 2015;30(1):48-52
Preoperative preparation of the hyperthyroid patient for thyroidectomy is imperative to avoid perioperative complications due to severe thyrotoxicosis. The mainstay of preparation is the administration of anti-thyroid drugs (ATD). When ATDs cause adverse reactions, an alternative regimen to prepare the patient for definitive management is crucial. We present the case of a 35-year-old Filipino female with Graves’ disease who developed methimazole-induced agranulocytosis. She refused to undergo radioactive iodine (RAI) therapy. She was admitted for thyroidectomy with elevated thyroid hormone levels. She was rapidly prepared for thyroidectomy using high-dose steroid, beta-adrenergic blocker, propylthiouracil (PTU) and Lugol’s solution. The patient’s free thyroxine level decreased after 8 days of treatment, without complications. She then underwent an uneventful subtotal thyroidectomy. In conditions with very limited options, although contraindicated, administration of another ATD may be the last alternative for patients who developed agranulocytosis.
Hyperthyroidism
;
Thyroidectomy
;
Agranulocytosis
;
Iodine
4.Conversion of primary hypothyroidism to hyperthyroidism: A case report
Journal of the ASEAN Federation of Endocrine Societies 2018;33(2):190-193
A 51-year-old Caucasian male developed Graves’ thyrotoxicosis following long-standing treatment for hypothyroidism. After a short period of treatment with carbimazole, he developed agranulocytosis and required total thyroidectomy. In this relevant case report, we review several pathogenetic mechanisms that explain the transformation of autoimmune hypothyroidism into Graves’ disease and the possible approaches to the management of agranulocytosis secondary to antithyroid medications. Further studies are required to determine the best way to manage severe thyrotoxicosis when agranulocytosis develops due to antithyroid medications.
Hypothyroidism
;
Antithyroid Agents
;
Carbimazole
;
Agranulocytosis
5.A case of Methimazole-Induced Cholestatic Jaundice With Agranulocytosis.
Sang Gu KANG ; Jong Oh BAE ; Eun Young LEE ; Seong Min LIM ; Sang Kun CHO ; Ji Hye KIM ; Sun Kyung SONG
Journal of Korean Society of Endocrinology 2005;20(5):519-523
Methimazole is a widely used and generally well-tolerated antithyroid agent. Adverse reactions occur in 1~5% of patients taking methimazole medication, but these are most commonly transient, benign leukopenia and a skin rash. Severe cholestatic jaundice, combined with agranulocytosis, has been known as a rare complication. Herein, a case of methimazole induced cholestatic jaundice, with agranulocytosis, is reported.
Agranulocytosis*
;
Exanthema
;
Humans
;
Jaundice, Obstructive*
;
Leukopenia
;
Methimazole
6.Two cases of congenital agranulocytosis treated with recombinant human granulocyte colony-stimulating factor.
Byoung Ho CHA ; Seung Hwan OH ; Chukl Joo LYU ; Chang Hyun YANG ; Kir Young KIM
Korean Journal of Hematology 1992;27(2):325-329
No abstract available.
Agranulocytosis*
;
Granulocyte Colony-Stimulating Factor*
;
Granulocytes*
;
Humans*
7.A Case of Clozapine-Induced Anemia and Thrombocytosis.
Journal of Korean Neuropsychiatric Association 2015;54(2):252-256
Clozapine is a well-known antipsychotic which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1-3% of patients). However, reports on blood dyscrasias like anemia and thrombocytosis after clozapine treatment are extremely rare. In some cases re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which may be a result of an immune reaction. This case report suggests that clinicians should monitor platelet count after re-treatment with clozapine.
Agranulocytosis
;
Anemia*
;
Clozapine
;
Neutropenia
;
Platelet Count
;
Thrombocytopenia
;
Thrombocytosis*
8.Agranulocytosis due to secondary exposure to antithyroid drugs in a relapsed Graves' disease patient.
Gwi Hong JEONG ; Seong Kyun KIM ; Dae Seong MYUNG ; Jin Ook CHUNG ; Dong Hyeok CHO ; Dong Jin CHUNG ; Min Young CHUNG
Korean Journal of Medicine 2008;75(3):362-366
Antithyroid drugs are the most common treatment modality for Graves' disease and are used for the treatment of relapsed Graves' disease in Korea. Agranulocytosis is a rare and severe complication of antithyroid drug therapy, and most cases occur within 3 month after drug treatment. Agranulocytosis can develop in patients who have relapsed Graves' disease and undergo a second course of antithyroid drugs with a prior uneventful course of drug therapy. We report a case of antithyroid drug-induced agranulocytosis in a relapsed Graves' disease patient who had undergone prior uneventful antithyroid drug therapy. We also present a review of the relevant literature.
Agranulocytosis
;
Antithyroid Agents
;
Graves Disease
;
Humans
;
Korea
;
Recurrence
9.A Case of Clozapine-Induced Eosinophilia Combined with Bilateral Pleural Effusion, Ascites, Cholecysctitis, and Hepatitis.
Hyun Ju HONG ; Chan Hyung KIM ; Dong Ho SONG ; Se Jun LEE ; Hong Shick LEE
Korean Journal of Psychopharmacology 1999;10(2):191-195
Several blood dyscrasias associated with clozapine have been well known to clinicians and potentially life threatening agranulocytosis has been widely reported. However, there is little report regarding incidence, progression and associated features of eosinophilia associated with clozapine. In clinical studies, the onset of eosinophilia usually occurs artier 3 to 5 weeks of treatment and rarely were cases fatal with medical complication. We report the first case of severe eosinophilia, bilateral pleural effusion, asicites, hepatitis and cholecystitis associated with clozapine that would be fatal. Eosinophilia occurred after 19 days of treatment with clozapine and all the clinical conditions improved along with interruption of clozapine treatment. It is suggested that eosinophilia may be more severe side effort than has ether been known and close hematologic monitoring should be done during early treatment of clozapine.
Agranulocytosis
;
Ascites*
;
Cholecystitis
;
Clozapine
;
Eosinophilia*
;
Ether
;
Hepatitis*
;
Incidence
;
Pleural Effusion*
10.Agranulocytosis and Neutropenia in Clozapine-Treated Patients.
Hyun Sang CHO ; Suk Kyoon AN ; Chan Hyung KIM ; Hong Shick LEE
Korean Journal of Psychopharmacology 1999;10(2):166-172
OBJECTIVE: Clozapine is effective in the treatment of refractory schizophrenic patients, but can cause reversible and fatal food dyscrasias. This study documents the incidence of agranulocytosis and neutropenia and the characteristics of patients with clozapine-inducted agranulocytosis. METHOD: An analysis was made of the hematological, demographic, and other characteristics data from Clozaril Patient Monitoring System(CPMS) data on 2139 patients on clozapine over about 3 years in Korea. RESULTS: During the study period, agranulocytosis developed in 11 patients and 9 (81.8%) patients occurred within 18 weeks. The cumulative incidence of this side effect was 0.57% at 6 months and 0.65% at 1 to 3 years and the crude incidence was 0.51%. Neutropenia occurred in 157 patients and 114(72.6%) ones developed within 18 weeks. The crude incidence of this blood abnormality was 6.9% at 1 year and 7.3% at 3 years. The cumulative incidence was 9.0% at 1 year and 28.7% at 3 years. The hazard rates far agranulocytosis and neutropenia peaked during the 3rd month and 2nd month, respectively. CONCLUSIONS: These results showed that the incidence of agranulocytosis in Korea may be lower than in USA and UK, at least during the early years of clozapine marketing. Also those suggest that the CPMS in Korea serves as a effective early warning system to promote the safety and benefits of clozapine.
Agranulocytosis*
;
Clozapine
;
Humans
;
Incidence
;
Korea
;
Marketing
;
Monitoring, Physiologic
;
Neutropenia*